fadrozole has been researched along with Cirrhosis in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antes, I; Barassin, C; Biemel, K; Hartmann, RW; Marchais-Oberwinkler, S; Müller-Vieira, U; Scherer, C; Voets, M | 1 |
| Antes, I; Biemel, K; Hartmann, RW; Marchais-Oberwinkler, S; Müller-Vieira, U; Scherer, C; Voets, M | 1 |
| Birk, B; Grombein, CM; Hartmann, RW; Heim, R; Lucas, S; Müller-Vieira, U; Negri, M; Ries, C; Schewe, KE | 1 |
| Brown, NJ | 1 |
| Beugels, IP; Cohuet, GM; de Gooyer, ME; Emmen, JM; Hermans, JJ; Hilbers, PA; Minnaard-Huiban, M; Ottenheijm, HC; Pieterse, K; Plate, R; Roumen, L; Ruijters, E; Smits, JF; van Essen, H | 1 |
1 review(s) available for fadrozole and Cirrhosis
| Article | Year |
|---|---|
Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.
Topics: Aldosterone; Animals; Aromatase Inhibitors; Cardiovascular System; Cytochrome P-450 CYP11B2; Endothelial Cells; Fadrozole; Fibrosis; Humans; Imidazoles; Inflammation; Kidney; Macrophages; Mineralocorticoid Receptor Antagonists; Myocardium; Myocytes, Cardiac; Pyridines; Reactive Oxygen Species; Receptors, Mineralocorticoid; Sodium, Dietary | 2013 |
4 other study(ies) available for fadrozole and Cirrhosis
| Article | Year |
|---|---|
Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Topics: Aromatase; Aromatase Inhibitors; Caco-2 Cells; Cell Membrane Permeability; Cytochrome P-450 CYP11B2; Fibrosis; Heart Failure; Humans; In Vitro Techniques; Liver; Microsomes, Liver; Models, Molecular; Myocardium; Naphthalenes; Schizosaccharomyces; Steroid 11-beta-Hydroxylase; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship | 2005 |
Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Topics: Animals; Binding Sites; Cell Line; Cell Membrane Permeability; Cricetinae; Cricetulus; Cytochrome P-450 CYP11B2; Fibrosis; Heart Failure; Humans; Indenes; Models, Molecular; Myocardium; Naphthalenes; Schizosaccharomyces; Structure-Activity Relationship | 2006 |
Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.
Topics: Animals; Cytochrome P-450 CYP11B2; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Fibrosis; Heart Failure; Humans; Male; Myocardium; Naphthalenes; Rats; Rats, Wistar; Structure-Activity Relationship | 2008 |
Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone.
Topics: Aldosterone; Animals; Canrenoic Acid; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type III; Drug Evaluation, Preclinical; Fadrozole; Fibrosis; Gene Expression Regulation; Heart; Heart Failure; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Rats; Rats, Inbred SHR; Stereoisomerism; Structure-Activity Relationship; Treatment Outcome | 2008 |